Report Highlights
- The U.S. market for therapeutics and diagnostics for women’s disorders was worth $29.9 billion in 2008. This should increase to $50.0 billion in 2013, for a compound annual growth rate (CAGR) of 10.9%.
- The rheumatoid arthritis and osteoporosis segment has the largest share of the market, generating $10.6 billion in 2008. This is expected to grow at a CAGR of 11.5% to reach $18.2 billion in 2013.
- Reproductive related therapies and diagnostics currently have the second largest market share, worth $5.9 billion in 2008. This should reach $7.5 billion in 2013, for a CAGR of 5.0%.
INTRODUCTION
- Autoimmune diseases
- Women’s cancer
- Gynecological diseases and infections
- Kidney and urological diseases and infections
- Reproductive-related therapies and diagnostics
- Rheumatoid arthritis and osteoporosis
- Examine BCC’s complete catalog of market research reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
Report Highlights
-
The total U.S. market for new therapeutics and diagnostics for women’s disorders was estimated at more than $25 billion in 2004 and is expected to reach nearly $41 billion in 2009, rising at an AAGR (average annual growth rate) of 10.3%.
-
Treatments for cancers specific to women will rise the fastest, at an AAGR of 12.6% and will lead revenues in 2009.
-
Reproductive-related therapies and diagnostics currently represent the largest market segment, but, rising at an AGR of 8.4%, will lag slightly by 2009.
-
Treatments for gynecological diseases and infections and for rheumatoid arthritis and osteoporosis also represent large market segments.
Report Highlights
-
The total current U.S. market for new therapeutics and diagnostics for women's disorders in 1999 reached $16.9 billion at the manufacturers' level. The growing numbers of women combined with the growing trend to take an active role in healthcare has driven growth in this market. By 2005, it is anticipated that revenues will likely reach $31.9 billion, growing at an average annual rate of 8.7%.
-
The reproductive-related therapeutics and diagnostics holds the largest market revenues position representing 31.9% and accounting for $5.4 billion of the total in 1999. Large numbers of women in the baby boomer age group, coupled with large numbers of the mini-boomers (daughters of the baby boomer generation), contributed to the reproductive-related therapeutics and diagnostics' dominate role in 1999. It is anticipated that the reproductive-related therapeutics and diagnostics will remain the largest market share throughout the forecast period as it crosses $10 billion by 2005.
Related Reports
Recent Reports
Gene Synthesis: Technologies and Global Markets
The global market for Gene Synthesis is estimated to increase from $2.0 billion in 2023 to reach $4.1 billion by 2028, at a compound annual growth rate (CAGR) of 15.8% from 2023 through 2028.
Flow Cytometry: Products, Technologies and Global Markets
The global market for flow cytometry products is expected to grow from $5.2 billion in 2023 to $8.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2029.
PEGylated Proteins Market
The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028.
Companion Diagnostics: Technologies and Markets
The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Top Trending Reports
Global Market for Cell and Gene Therapy
The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028.
Peptide Synthesis: Global Markets
The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2023 to 2028.
Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets
The global market for medical magnetic resonance imaging (MRI) is expected to grow from $7.2 billion in 2023 and projected to reach $9.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 6.4% during the forecast period of 2023 to 2028.
Oligonucleotides: Global Markets
The global market for oligonucleotides is expected to grow from $7.0 billion in 2023 and projected to reach $11.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.
3D Cell Cultures: Technologies and Global Markets
The global market for 3D cell culture is estimated to increase from $4.6 billion in 2023 to reach $14.8 billion by 2028, at a compound annual growth rate (CAGR) of 26.5% from 2023 through 2028.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More